Carly Elston, MD
Dermatology · Birmingham, ALNPI 1023429396
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,740 of the $4,217 with a category attached, or 88.7%. Boehringer Ingelheim accounts for 88.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $3,878 and has fallen 95.1% since, to $189 in 2024. That places this record below the midpoint for dermatology clinicians in AL, where the typical reported total is $4,251.
Across 11 payments — averaging $383.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$4K
- Novartis$138
- Pfizer$135
- Dermira, Inc.$125
- UCB, Inc.$53
- Dermavant Sciences, Inc.$26
What the payments were for
- Consulting fees$3,74089%
- Food & beverage$47711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $3,740 |
| Novartis | 5 | $138 |
| Pfizer | 1 | $135 |
| Dermira, Inc. | 1 | $125 |
| UCB, Inc. | 2 | $53 |
| Dermavant Sciences, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,217 in reported general payments places this provider in the 45th percentile of 168 dermatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 26 | $403,143 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $385,913 |
| Dupixent PenDupilumab | 29 | $102,665 |
| EnbrelEtanercept | 11 | $80,012 |
| Sodium Chloride0.9 % Sodium Chloride | 13 | $501 |
| Diphenhydramine Hcl | 13 | $131 |
| Ondansetron HclOndansetron Hcl/Pf | 13 | $59 |
| FamotidineFamotidine/Pf | 13 | $57 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Birmingham
- James KrellBirmingham$944K
- Julie HarperBirmingham$920K
- Corey HartmanBirmingham$573K
- Boni ElewskiBirmingham$271K
- Tiffany MayoBirmingham$256K
- Kristy CurlBirmingham$158K
- Sarah Lauren HugheyBirmingham$143K
- Megan CherryBirmingham$137K
- Ann HillBirmingham$56K
- Lauren GrahamBirmingham$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.